Acute Hemorrhagic Encephalomyelitis in the Context of MOG Antibody-Associated Disease. Comment on Chen et al. Rapid Progressive Fatal Acute Hemorrhagic Encephalomyelitis. Diagnostics 2023, 13, 2481

Sohyeon Kim; Mi-Yeon Eun; Jae-Joon Lee; Hung Youl Seok

doi:10.3390/diagnostics13193148

Acute Hemorrhagic Encephalomyelitis in the Context of MOG Antibody-Associated Disease. Comment on Chen et al. Rapid Progressive Fatal Acute Hemorrhagic Encephalomyelitis. Diagnostics 2023, 13, 2481

Diagnostics (Basel). 2023 Oct 7;13(19):3148. doi: 10.3390/diagnostics13193148.

Authors

Sohyeon Kim¹, Mi-Yeon Eun², Jae-Joon Lee¹, Hung Youl Seok¹

Affiliations

¹ Department of Neurology, Dongsan Hospital, Keimyung University School of Medicine, Daegu 42601, Republic of Korea.
² Department of Neurology, School of Medicine, Kyungpook National University Chilgok Hospital, Daegu 41404, Republic of Korea.

Abstract

The study by Chen et al. of a 56-year-old man diagnosed with acute hemorrhagic encephalomyelitis (AHEM) had a significant impact on us. The authors provided a comprehensive account of their diagnostic journey and emphasized the need to differentiate myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) from AHEM. However, recent research suggests that AHEM may not be an isolated entity, but rather a phenotype within MOGAD. The patient's clinical presentation included MRI brain lesions characteristic of MOGAD in addition to hemorrhagic abnormalities. These findings raise the possibility that AHEM in this case represents a MOGAD phenotype. In conclusion, it is important to recognize the potential association between AHEM and MOGAD, especially when distinct MOGAD brain MRI patterns are present, as in this case.

Keywords: acute hemorrhagic encephalomyelitis; myelin oligodendrocyte glycoprotein.